Q-omics provides the consensus-scored POLR3B profile across patient tissues and cancer cell-line models. POLR3B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, POLR3B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, POLR3B RNA expression shows 19,975 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where POLR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3B survival associations across molecular data types. POLR3B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3B RNA expression–survival associations across cancer types. High POLR3B expression shows unfavorable associations in LUAD, BLCA, OV and LGG, but favorable associations in UCS and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for POLR3B RNA expression.
This table summarizes POLR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3B shows lower tumor expression in KIRC, THCA and LUAD and higher tumor expression in BLCA, LUSC and COAD. The KIRC box plot shows higher POLR3B RNA expression in normal versus tumor tissue (log2 FC = −0.917, t-test p < 0.001).
This table shows molecular features associated with POLR3B in patient tissues and cancer cell lines. In patient samples, POLR3B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
